


 Cite this: *RSC Adv.*, 2022, **12**, 26016

# Determination of 12 anti-obesity drugs in human plasma by a 96-well protein precipitation plate using HPLC-MS†

 Tengteng Ping,<sup>a</sup> Min Zheng,<sup>b</sup> Pingping Zhang,<sup>c</sup> Tianhao Yan,<sup>a</sup> Xufeng Miao,<sup>d</sup> Ke Wang<sup>\*e</sup> and Kaoqi Lian<sup>ib\*af</sup>

An analytical method was developed and validated for the simultaneous determination of 12 anti-obesity drugs (methylephedrine (MER), amphetamine (AMP), fenfluramine (FEN), bupropion (BUP), fluoxetine (FLU), sibutramine (SIBU), bisacodyl (BISA), bumetanide (BUM), lovastatin (LOVA), simvastatin (SIM), rimonabant (RIMO), and fenofibrate (FENO)) in human plasma by a 96-well protein precipitation plate combined with high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). The 96-well protein precipitation plate was chosen for simultaneous pretreatment of large sample volumes, making the whole process more efficient and faster. Drugs were separated on an Agilent Poroshell 120 EC-C18 column, and detected by MS/MS under multiple reaction monitoring (MRM) mode. The developed method was validated in terms of linearity, matrix effect, accuracy and precision. A good linearity was obtained in the range of 0.1–20.0 ng mL<sup>-1</sup> for fenfluramine, bupropion, fluoxetine, sibutramine, bisacodyl, and rimonabant; and 0.5–20.0 ng mL<sup>-1</sup> for methylephedrine, amphetamine, bumetanide, lovastatin, simvastatin, and fenofibrate with a correlation coefficient above 0.995. The method was fully validated with an acceptable accuracy of 75.63–108.21%, matrix effect of 80.41–117.71% except for fenofibrate (76.07% at low concentration levels), and precision of 0.32–13.12%. Owing to the advantages of simple operation, high accuracy and sensitivity, this method is suitable for the rapid and simultaneous detection of 12 anti-obesity drugs in human plasma, providing support for clinically monitoring the development of adverse reactions and guiding the rational and appropriate use of weight-loss drugs for obese people.

 Received 2nd June 2022  
 Accepted 6th September 2022

DOI: 10.1039/d2ra03423a

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## 1. Introduction

Obesity is a chronic metabolic disease, which involves the accumulation of abnormal or excessive fat that can impair health. The number of obese people between the ages of 5 and 19 years increased more than tenfold from 11 million to 124 million worldwide from 1975 to 2016.<sup>1</sup> Once considered a problem in high-income countries, obesity is now rising in low- and middle-income countries, especially in urban

settings.<sup>2</sup> This makes obesity a worldwide health concern.<sup>3,4</sup> Obese people have a significantly higher risk of developing non-communicable diseases, such as cardiovascular disease<sup>5–7</sup> (mainly heart disease and stroke) and certain cancers<sup>7</sup> (endometrial, breast, ovarian, prostate, liver, gallbladder, kidney and colon). Moreover, obesity also has many adverse effects on human fertility.<sup>8,9</sup> Further, the psychological effects of obesity are even greater in children and adolescents, who are more likely to suffer from depression.<sup>10</sup>

Regarding the treatment, diet and exercise are the most commonly used strategies, but they are also difficult to persist, making the use of weight-loss drugs more promising. Long-term, effective and safe anti-obesity medications are more successful when used in combination with behavioural approaches.<sup>11</sup> A variety of drugs are available for long-term use, which can be classified based on the mechanism of action, as appetite suppressants such as fenfluramine, sibutramine, rimonabant, and so forth; central excitatory drugs such as methylephedrine, amphetamine, bupropion and fluoxetine, which increase energy expenditure; inhibitors of intestinal digestion and absorption, for example, bisacodyl; diuretics, for example, bumetanide; lipid-lowering medicines, such as

<sup>a</sup>School of Public Health, Hebei Medical University, Shijiazhuang, 050017, China. E-mail: [liankq@hebmh.edu.cn](mailto:liankq@hebmh.edu.cn)
<sup>b</sup>Jinan Centre for Disease Control and Prevention, Jinan, 250000, China

<sup>c</sup>Department of Reproductive Genetic Family, Hebei General Hospital, Shijiazhuang, Hebei, 050000, China

<sup>d</sup>Physical Education Department, Hebei Medical University, Shijiazhuang, 050017, China. E-mail: [wkecdc@163.com](mailto:wkecdc@163.com)
<sup>e</sup>Shijiazhuang Centre for Disease Control and Prevention, Shijiazhuang, 050011, China

<sup>f</sup>Hebei Key Laboratory of Environment and Human Health, Shijiazhuang, 050017, China

 † Electronic supplementary information (ESI) available. See <https://doi.org/10.1039/d2ra03423a>


lovastatin, simvastatin, and fenofibrate. To make the results more representative and comprehensive, these drugs listed above were selected as analytes for testing.

However, many weight-loss medications can be very harmful. Recently, damage to various organs, such as cardiovascular system,<sup>12–14</sup> digestive system,<sup>15–17</sup> liver,<sup>18</sup> and nervous system,<sup>19–21</sup> malnutrition, and reproductive system<sup>22</sup> caused by the long-term use of weight-loss pills has been reported. Also, many drugs are dose dependent and addictive with serious side effects, when used in excess. Hence, testing the blood levels of clinically approved and banned weight-loss drugs to monitor the development of adverse reactions is essential.

Various methods are used for determining anti-obesity drugs, including spectroscopic methods, such as near infrared spectroscopy (NIRS) and Raman spectroscopy (RS); chromatographic methods, such as thin-layer chromatography (TLC), liquid chromatography (LC), gas chromatography-tandem mass spectrometry (GC-MS/MS), and liquid chromatography-tandem mass spectrometry (LC-MS/MS);<sup>23–26</sup> ion mobility spectrometry (IMS), and so forth. The main target is, however, the illegal addition of slimming drugs in food or drugs. The sample measured in this experiment is blood with a complex matrix. LC-MS/MS has good separation efficacy and high specificity and sensitivity, making it suitable for the accurate quantification of target analytes in blood.

The protein precipitation uses organic solvents miscible with water, such as methanol, acetonitrile, and so forth, to change the hydrogen bonds among protein molecules and thus denature and agglutinate them for the removal of interference from large molecules such as proteins. Based on this theory, the 96-well protein precipitation plate in the experiment can effectively block common protein precipitating agents such as acetonitrile, thus avoiding penetration. If the number of samples is large, the 96-well structure of the plate can effectively save time compared with the traditional protein precipitation method, which makes the whole pre-treatment process more efficient and automated.<sup>27,28</sup>

By optimizing the chromatographic separation and mass spectrometric detection conditions, an analytical method was developed for the simultaneous determination of 12 diet pills [methylephedrine (MER), amphetamine (AMP), fenfluramine (FEN), bupropion (BUP), fluoxetine (FLU), sibutramine (SIBU), bisacodyl (BISA), bumetanide (BUM), lovastatin (LOVA), simvastatin (SIM), rimonabant (RIMO), and fenofibrate (FENO)] in human plasma. The detection of the 12 anti-obesity drugs could be completed within 20 min. The 96-well protein precipitation was suitable for simultaneous pre-treatment of a large number of complex samples and could effectively extract targeted drugs. This method was sensitive and specific, with a low detection limit and high accuracy, and could determine the target analytes in blood samples.

## 2. Experimental

### 2.1. Reagents and instruments

Standards: methylephedrine hydrochloride, bupropion hydrochloride, amphetamine sulfate, fenfluramine, fluoxetine

hydrochloride, sibutramine hydrochloride, bixarcomidine, bumetanide, lovastatin, simvastatin and fenofibrate were purchased from the National Institutes for Food and Drug Control (Beijing, China), and rimonabant was purchased from QCC (USA), and the purity was 100%. Chromatographically pure acetonitrile, methanol, formic acid, and acetic acid were purchased from Dima Technology (Beijing, China). Instruments: Agilent 1260 series liquid chromatograph (Agilent), Agilent 6460 triple quadrupole mass spectrometer (Agilent), Synergy UV water purifier (Merck, Germany), TM-1F vortex instrument (Wiggins, Germany), high-speed centrifuge (Hunan Xiang Yi Laboratory Instrument Development Co., Ltd.), SPE-M 96 solid phase extractor device (Agela Technologies), NV-G-S nitrogen blowing device (Agela Technologies), 96-well protein precipitation plate (Nunc, ThermoFisher, Pittsburgh, PA).

### 2.2. HPLC-MS/MS conditions

A HPLC-MS/MS instrument was used to analyse the 12 target compounds. The chromatographic column was an Agilent Poroshell 120 EC-C18 column (3.0 mm × 50 mm, 2.7 μm); the mobile phase A was 0.1% formic acid water (v/v), the mobile phase B was acetonitrile with 0.1% formic acid. The gradient elution procedure was as follows: 0 to 2.0 min, 15% B; 2.0 to 4.0 min, 15% to 90% B; 4.0 to 13.0 min, 90% B; 13.0 to 14.0 min, 90% to 15% B; 14.0 to 20.0 min, 15% B; flow rate was 0.3 mL min<sup>-1</sup>, the column temperature was 30 °C, and the injection volume was 2 μL.

Electrospray ionization source (ESI); positive ion mode (+); multiple reaction monitoring (MRM); drying gas flow rate: 11 L min<sup>-1</sup>; drying gas temperature: 300 °C; capillary voltage: 4000 V. The monitored ions, the retention time, collision energy, and fragmentor voltage of analytes are shown in Table 1.

### 2.3. Reference stock solution and quality control sample preparation

The refined weighing MER, AMP, FEN, BUP, FLU, SIBU, BISA, BUM, LOVA, SIM, RIMO and FENO were dissolved in methanol, respectively. Then, a stock solution with a mass concentration of 500 μg mL<sup>-1</sup> for each drug was prepared and stored in a -20 °C refrigerator. When in use, the standard curve working solutions of 12 diet drugs were diluted proportionally with methanol. The concentrations of standard curve solutions of BUP, FEN, SIBU, RIMO, FLU, and BISA ranged from 0.1 ng mL<sup>-1</sup> to 20.0 ng mL<sup>-1</sup> (0.1, 0.5, 1.0, 5.0, 10.0, and 20.0 ng mL<sup>-1</sup>); MER, AMP, BUM, LOVA, SIM, and FENO ranged from 0.5 ng mL<sup>-1</sup> to 20.0 ng mL<sup>-1</sup> (0.5, 1.0, 5.0, 10.0, and 20.0 ng mL<sup>-1</sup>).

Take 100 μL blank plasma, add a certain concentration (the volume was 10 μL) of mixed standard solution to prepare low-, medium- and high-concentration levels of quality control (QC) samples. The low-, medium- and high-concentration levels of MER, AMP, FEN, BUP, FLU, SIBU, BISA, BUM, LOVA, SIM, RIMO and FENO are 0.8, 10.0, and 16.0 ng mL<sup>-1</sup>, respectively.

### 2.4. Samples

Blood samples were collected from the Physical Examination Centre of the 980th Hospital of the Chinese People's Liberation



Table 1 The MS/MS monitored ions, fragmentor voltage, collision energy and retention time of the 12 anti-obesity medicines

Compounds	Precursor ion ( <i>m/z</i> )	Product ion ( <i>m/z</i> )	Fragmentor voltage (V)	Collision energy (eV)	Retention time (min)
MER	180.1	162.1 <sup>a</sup>	50	13	1.571
		147.0	50	25	
AMP	136.1	91.0 <sup>a</sup>	14	21	1.766
		119.0	14	5	
FEN	232.1	158.9 <sup>a</sup>	80	33	6.624
		187.0	80	13	
BUP	240.1	184.0 <sup>a</sup>	80	9	6.473
		131.0	80	33	
FLU	310.1	44.2 <sup>a</sup>	80	13	7.120
		148.0	80	5	
SIBU	280.2	124.9 <sup>a</sup>	80	33	7.248
		138.9	80	13	
BISA	362.1	183.9 <sup>a</sup>	80	37	7.427
		226.0	80	17	
BUM	365.1	240.0 <sup>a</sup>	80	21	7.743
		184.1	80	25	
LOVA	405.3	285.1 <sup>a</sup>	75	9	9.736
		199.1	75	9	
SIM	419.3	285.0 <sup>a</sup>	75	9	10.318
		199.1	75	21	
RIMO	463.1	362.8 <sup>a</sup>	80	37	10.433
		84.1	80	33	
FENO	361.1	233.0 <sup>a</sup>	80	17	10.886
		138.9	80	33	

<sup>a</sup> Quantitative ion.

Army Joint Logistic Support Force (Hebei) in this study. The involving human participants were approved by the Ethics Committee of Hebei Medical University (Approval Number 2020067).

### 2.5. Sample pre-treatment

The peripheral venous blood collected from volunteers was centrifuged to collect the plasma, which was stored at  $-20\text{ }^{\circ}\text{C}$ . The plasma samples were naturally thawed, shaken separately to homogenize before use, and processed through a 96-well protein precipitation plate for testing. Then, 300  $\mu\text{L}$  of acetonitrile was added to the 96-well precipitation plate, followed by 100  $\mu\text{L}$  of plasma. The samples were shaken, mixed, and rested for 5 min. The precipitation plate with the collection plate attached was transferred to a positive-pressure device. The solution was collected using positive pressure, blown to dryness at  $45\text{ }^{\circ}\text{C}$  under nitrogen, and reconstructed with 200  $\mu\text{L}$  of methanol solution for analysis. If reconstitution volume is any smaller, the target substance will not be completely dissolved.

## 3. Results and discussion

### 3.1. Optimization of chromatographic conditions

The 12 anti-obesity drugs have different chemical properties and differ significantly in polarity, which make it more difficult to achieve good separation. After a variety of acetonitrile, 0.1% formic acid water–acetonitrile, 0.1% acetic acid water–acetonitrile, 1.0% formic acid water–acetonitrile, and 0.1%

formic acid water–0.1% formic acid acetonitrile, it was found that the peak shape was better when the mobile phase was acetonitrile–water (each containing 0.1% formic acid). After repeated trials, the gradient elution procedure for the experiment was established. The result indicated that the separation of each analyte was good and the baseline was smooth.

### 3.2. Selection of mass spectrometry conditions

A hydrogen ion could be easily added to all 12 analytes to form a positively charged  $[\text{M} + \text{H}]^+$  ion peak. Therefore, the positive-ion mode was used for detection. The parameters such as declustering potential and collision energy for each analyte were optimized to achieve higher sensitivity, and the fragment ions with the highest response values were selected for quantification.

### 3.3. Optimization of pre-treatment condition

**3.3.1 Selection of sample pre-treatment methods.** The present method was compared with the conventional protein precipitation. 100  $\mu\text{L}$  of  $10.0\text{ ng mL}^{-1}$  plasma samples were added into 300  $\mu\text{L}$  of acetonitrile for protein precipitation. The present method was done according to Section 2.5. The traditional protein precipitation involves mixing the precipitant with the sample, centrifuging the mixture, and feeding it into the instrument for testing.<sup>29</sup> Then the solution was blown to dryness at  $45\text{ }^{\circ}\text{C}$  under nitrogen, and reconstructed with 200  $\mu\text{L}$  of methanol solution for analysis. The efficiency of the pre-treatment was evaluated by comparing the recovery of the






Fig. 1 Effect of two pre-treatment methods on recovery of analytes.

target analytes at the same concentration,  $10.0 \text{ ng mL}^{-1}$ . The results are shown in Fig. 1. The recoveries of the present method were significantly better than those of the conventional protein precipitation method. Almost all target recoveries were increased by 50% and reached 80%. In particular, those of FEN, SIBU, BISA, increased from 20%, 30%, and 20% to 103%, 89%, and 85%, respectively, after using this method. This method, in addition, eliminates the need for centrifugation and filtrate transfer. The filtrate can be collected by applying positive pressure after mixing the precipitant with the sample. The sedimentation plate is a 96-well structure, which can handle 96 samples at the same time. It also shortens the time and improves the laboratory processing sample throughput, effectively speeding up the work process.

**3.3.2 Selection of precipitation reagents.**  $100 \mu\text{L}$  of  $10.0 \text{ ng mL}^{-1}$  plasma samples were added into  $300 \mu\text{L}$  of different precipitation reagents, methanol and acetonitrile for protein precipitation. Then the experiment was done as shown in Section 2.5. 3 replicates were done for every test. The precipitation performance was assessed by comparing the recovery. The result




Fig. 2 Effect of different precipitants on the recovery of analytes.

suggested that acetonitrile was used for protein precipitation with better results and higher recovery, as shown in Fig. 2. Therefore, acetonitrile was chosen as the protein precipitant. Solvent volumes for precipitated proteins were in the range of  $200\text{--}400 \mu\text{L}$  and a volume ratio of protein precipitant to blood sample was between  $2 : 1$  and  $4.3 : 1$ .<sup>28,30,31</sup> Furthermore, the solvent volumes in this range had little effect on recovery. Hence  $300 \mu\text{L}$  acetonitrile was chosen as the precipitation solvent.

### 3.4. Methodological validation and evaluation

**3.4.1 Precision and accuracy.** Blank plasma samples were taken to prepare QC samples of low, medium, and high concentrations and processed according to the developed sample pre-treatment method. Three parallel samples were set up for each quality concentration, and each sample was measured three times in parallel, that is to say, each quality concentration was measured nine times; 3 days were measured continuously. The precision of the developed method was evaluated in terms of intra- and inter-day repeatability ( $n = 3$ ) and is represented as percent relative standard deviation (%RSD). The %RSD values were found to be  $\leq 13.04\%$  for intra-day and  $\leq 13.12\%$  for inter-day. The accuracy of the developed method was evaluated by means of recovery assays on spiked blanks. It was obtained by comparing the added mass concentration with the measured mass concentration of the sample calculated with the corresponding standard curve. The results are shown in Table 2. The accuracy ranged from 75.63% to 108.21%. The results indicated that the method was accurate, reliable, and suitable for the monitoring of 12 diet drugs in plasma.

**3.4.2 Selectivity.** Two blank plasma samples were taken, one of which was spiked with the standard working solution mixture (the concentrations of the 12 anti-obesity drugs were all  $10 \text{ ng mL}^{-1}$ ). The two samples were processed according to the sample pretreatment and then analyzed using HPLC-MS/MS. The chromatogram of the spiked sample is shown in Fig. 3.

A substance can be identified as a target substance only if the precursor ion, product ion, and retention time all agree with the target substance. Based on this fact, although the peaks of some target substances were not completely separated, it did not affect the characterization of the interesting substances. For example, for target substances 10 and 11, although the chromatograms were not completely separated, their precursor ions and daughter ions were so different that they were able to be correctly characterized and quantified. In order to cover as many commercially available anti-obesity drugs as possible and to make the study more comprehensive, all 12 weight loss drugs were analysed.

**3.4.3 Calibration curve and linearity.** Six blank plasma samples were added to the standard working solution mixture and processed according to the method of sample pre-treatment to obtain the standard plasma mixture at the following final concentrations: BUP, FEN, SIBU, RIMO, FLU, and BISA at  $0.1, 0.5, 1.0, 5.0, 10.0,$  and  $20.0 \text{ ng mL}^{-1}$ , respectively; and MER, AMP, BUM, LOVA, SIM, and FENO at  $0.5, 1.0, 2.0, 5.0, 10.0,$  and  $20.0 \text{ ng mL}^{-1}$ , respectively. Linear regression analysis was performed with the horizontal coordinate represented by the mass concentration of each analyte in plasma (X)



Table 2 Intra-day and inter-day precision and accuracy of analytes ( $n = 3$ )

Compounds	Spiked (ng mL <sup>-1</sup> )	ME (%)	Precision (RSD%)		Accuracy (%)
			Inter-day	Intra-day	
MER	0.8	117.71	4.07	3.99	88.17
	10.0	95.09	2.52	3.56	108.21
	16.0	108.41	1.93	0.32	100.71
AMP	0.8	98.19	13.12	13.04	96.23
	10.0	94.37	2.37	2.98	107.41
	16.0	103.00	3.61	0.59	95.11
FEN	0.8	108.07	2.22	2.89	102.06
	10.0	99.16	1.64	0.58	102.20
	16.0	111.60	1.86	2.32	102.91
BUP	0.8	114.11	1.87	3.32	99.48
	10.0	96.91	0.92	2.75	103.65
	16.0	111.72	1.97	2.13	101.71
FLU	0.8	107.50	1.53	2.64	94.00
	10.0	95.76	1.15	2.64	105.49
	16.0	110.99	0.97	0.17	101.65
SIBU	0.8	108.78	5.38	7.22	87.29
	10.0	95.43	0.84	4.50	91.37
	16.0	110.12	1.85	2.86	88.32
BISA	0.8	98.09	2.97	1.87	86.77
	10.0	96.65	1.08	1.43	85.39
	16.0	110.14	1.60	0.62	102.82
BUM	0.8	80.62	5.34	7.35	86.17
	10.0	93.84	4.72	1.29	99.02
	16.0	107.51	4.86	2.15	94.54
LOVA	0.8	84.95	5.77	6.01	95.16
	10.0	88.62	1.67	4.47	84.39
	16.0	84.08	4.61	4.12	84.03
SIM	0.8	91.76	11.92	8.33	75.63
	10.0	81.79	3.36	10.15	85.72
	16.0	93.07	4.42	3.63	81.65
RIMO	0.8	105.96	1.42	7.83	99.92
	10.0	98.58	1.45	2.14	101.99
	16.0	112.72	2.01	2.51	102.87
FENO	0.8	76.07	5.25	6.94	84.76
	10.0	80.41	3.50	7.83	83.21
	16.0	84.37	8.59	4.33	76.98

and the vertical coordinate represented by the peak area of the substance (Y). Then, a standard curve was made, and the slope and the correlation coefficient were obtained. The method detection limits (MDL) were calculated at three times the signal-to-noise ratio (S/N), and the method quantification limits (MQL) were calculated at ten times S/N. The results are shown in Table 3. The standard working solution with minimum linear concentrations of each drug was analysed once directly by HPLC/MS. Check the signal-to-noise ratio of the instrument at this concentration. Then calculate the instrumental detection limits (IDL) and instrumental quantification limits (IQL) based on the proportional relationship between the solution concentration and the signal-to-noise ratio. Similarly, IDL were at three times S/N, and IQL were at ten times S/N, as is shown in Table S1.† The targets showed a good linear correlation in a certain concentration range with the correlation coefficients greater than 0.99. The MDL ranged from 0.01 to 0.24 ng mL<sup>-1</sup>, and the MQL ranged from 0.10 to 0.50 ng mL<sup>-1</sup>. By comparison with the published literature, such as Júlia Martinelli Magalhães Kahl *et al.*<sup>32</sup> quantified amphetamine in oral liquids using LC/MS in 2021, and LOQ was 20.0 ng mL<sup>-1</sup>. Martin Kertys *et al.*<sup>33</sup> determined fluoxetine in human plasma by LC-MS/MS, and LOQ was 1.0 ng mL<sup>-1</sup>. Yijun Li *et al.*<sup>34</sup> detected bumetanide in serum and brain tissue using LC/MS, and LOQ was 1.0 ng mL<sup>-1</sup>. Hence the LOQ obtained in this experiment are better than other methods and good enough to accomplish the requirements for the analysis of those metabolite in plasma.

**3.4.4 Matrix effect.** An appropriate amount of blank human plasma was processed according to sample pre-treatment to obtain a blank plasma matrix solution. Then, the mixed reference working solution of the target analytes was added to it to prepare samples at three mass concentration levels: low, medium, and high for detection. The measured peak area (A) of the tested substance was compared with that (B) obtained by directly injecting the standard solution of the corresponding mass concentration into the LC system, and the matrix effect (ME) ( $A/B \times 100\%$ ) of this method was calculated. ME greater




Fig. 3 Typical chromatograms of blank plasma spiked reference compounds (1. MER, 2. AMP, 3. FEN, 4. BUP, 5. FLU, 6. SIBU, 7. BISA, 8. BUM, 9. LOVA, 10. SIM, 11. RIMO, 12. FENO).



Table 3 Regression equations and limit of quantification of analytes

Compounds	Linear equation	Linear range (ng mL <sup>-1</sup> )	R <sup>2</sup>	LOD (ng mL <sup>-1</sup> )	LOQ (ng mL <sup>-1</sup> )
MER	Y = (570 ± 20) x + (400 ± 200)	0.50–20.0	0.9954	0.16	0.50
AMP	Y = (690 ± 20) x + (300 ± 200)	0.50–20.0	0.9976	0.13	0.50
FEN	Y = (2870 ± 80) x + (1200 ± 800)	0.10–20.0	0.9966	0.03	0.10
BUP	Y = (2610 ± 80) x + (600 ± 700)	0.10–20.0	0.9963	0.03	0.10
FLU	Y = (3840 ± 120) x + (1100 ± 1100)	0.10–20.0	0.9964	0.02	0.10
SIBU	Y = (2230 ± 60) x + (500 ± 600)	0.10–20.0	0.9971	0.04	0.10
BISA	Y = (6330 ± 200) x + (2000 ± 2000)	0.10–20.0	0.9959	0.01	0.10
BUM	Y = (220 ± 10) x + (100 ± 100)	0.50–20.0	0.9984	0.22	0.50
LOVA	Y = (250 ± 10) x + (100 ± 100)	0.50–20.0	0.9975	0.20	0.50
SIM	Y = 200x + 100	0.50–20.0	0.9994	0.24	0.50
RIMO	Y = (1690 ± 60) x + (500 ± 600)	0.10–20.0	0.9952	0.05	0.10
FENO	Y = (570 ± 20) x + (200 ± 200)	0.50–20.0	0.9969	0.16	0.50

Table 4 Comparison of the developed method to the other approaches used in the extraction of anti-obesity drugs in plasma

Instrument	Pre-processing method	The number of analytes	LOQ (ng mL <sup>-1</sup> )	Recovery (%)	Ref.
LC-MS/MS	96-Well protein precipitation plate	12	0.1–0.5	75.63–108.21	This work
GC-MS	SPME	3	5.0	85.58–108.33	38
LC-ESI-MS/MS	LLE	3	0.05	88.0–113.1	35
LC-MS/MS	LLE	3	0.5–2	89–114	36
LC-HRMS/MS	LLE	7	1	80–120	37
LC-MS/MS	Ostro 96-well plate	5	0.2–1.0	80.2–91.1	33

than 120% are considered enhanced and less than 80% are inhibited. The finding that ME is from 80 to 120% indicates that the matrix enhancement/inhibitory effect is acceptable. The MEs of each analyte in this experiment at low, medium, and high concentrations were negligible except from FENO, which had a slight matrix inhibition effect (76.07%) at low concentration levels. The remaining 11 analytes were in the range of 80–120%, which was 80.41–117.71%. The results are shown in Table 2.

**3.4.5 Method comparison.** Analytical performances of the developed LC-MS/MS method for the determining weight loss drugs were mainly compared with the reported similar methods. As shown in Table 4, LLE were the most used pre-treatment methods.<sup>35–37</sup> However, compared with LLE, 96-well protein precipitation plate was more convenient, fast and high throughput. More importantly, only the new method provided a comprehensive and detailed quantification of weight loss drugs commercially available.<sup>33,35–38</sup> In comparison, the modified method was developed for the determination of 12 anti-obesity drugs in plasma with suitable recoveries and the low LOQs, which showed high throughput and high sensitivity.

Shortly, the method was simple to operate with low reagent consumption, short analysis time, and simultaneous pre-treatment for large batch samples, greatly saving labour consumption and speeding up the experimental process.

## 4. Conclusions

A specific and sensitive method was successfully developed for the simultaneous determination of 12 weight-loss drugs in

plasma with negligible matrix interference. The samples were processed through a 96-well protein precipitation plate, separated on a Agilent Poroshell 120 EC-C18 column, and detected by HPLC-MS/MS with ESI in positive ion mode under MRM mode. This method was validated regarding its analytical range, precision, recovery, selectivity and ME. Based on the experimental results, the method is simple, rapid, sensitive and could process nearly 100 samples simultaneously, which can be applied in accurate and high throughput detection of anti-obesity drugs, providing support for clinically monitoring the development of adverse reactions and guiding the rational and appropriate use of weight-loss drugs for obese people.

## Author contributions

Tengteng Ping: methodology; investigation; validation; data curation; formal analysis; visualization; writing – original draft; Min Zheng: formal analysis, methodology, writing – original draft. Pingping Zhang: methodology, validation, writing – original draft. Tianhao Yan: supervision, validation. Xufeng Miao: methodology, visualization. Ke Wang: data curation, formal analysis, writing – original draft, funding acquisition. Kaoqi Lian: conceptualization, project administration, resources, writing – review & editing. All authors have read and agreed to the published version of the manuscript.

## Conflicts of interest

The authors declare no conflict of interest.



## Acknowledgements

This work was supported by the Central Government guides the development of local science and technology project of Hebei Province (226Z7708G), and the key research and development program of Hebei Province, China (223777116D).

## References

- 1 L. Abarca-Gómez, Z. A. Abdeen, Z. A. Hamid, N. M. Abu-Rmeileh, B. Acosta-Cazares, C. Acuin, R. J. Adams, W. Aekplakorn, K. Afsana, C. A. Aguilar-Salinas, C. Agyemang, A. Ahmadvand, W. Ahrens, K. Ajlouni, N. Akhtaeva and H. M. Al-Hazzaa, *Lancet*, 2017, **390**, 2627–2642.
- 2 L. Li, N. Sun, L. Zhang, G. Xu, J. Liu, J. Hu, Z. Zhang, J. Lou, H. Deng, Z. Shen and L. Han, *Global Health Action*, 2020, **13**, 1795438.
- 3 A. M. Prentice, *Int. J. Epidemiol.*, 2006, **35**, 93–99.
- 4 J. Shen, A. Goyal and L. Sperling, *Cardiol. Res. Pract.*, 2012, 178675.
- 5 D. Garcia-Labbe, E. Ruka, O. F. Bertrand, P. Voisine, O. Costerousse and P. Poirier, *Can. J. Cardiol.*, 2015, **31**, 184–194.
- 6 M. D. Jensen, D. H. Ryan, C. M. Apovian, J. D. Ard, A. G. Comuzzie, K. A. Donato, F. B. Hu, V. S. Hubbard, J. M. Jakicic, R. F. Kushner, C. M. Loria, B. E. Millen, C. A. Nonas, F. X. Pi-Sunyer, J. Stevens, V. J. Stevens, T. A. Wadden, B. M. Wolfe and S. Z. Yanovski, *Circulation*, 2014, 129.
- 7 E. A. Silveira, N. Kliemann, M. Noll, N. Sarrafzadegan and C. de Oliveira, *Obes. Rev.*, 2021, **22**, e13088.
- 8 A. Salas-Huetos, L. Maghsoumi-Norouzabad, E. R. James, D. T. Carrell, K. I. Aston, T. G. Jenkins, N. Becerra-Tomas, A. Z. Javid, R. Abed, P. J. Torres, E. M. Luque, N. D. Ramirez, A. C. Martini and J. Salas-Salvado, *Obes. Rev.*, 2021, **22**, e13082.
- 9 J. Simoes-Pereira, J. Nunes, A. Aguiar, S. Sousa, C. Rodrigues, J. Sampaio Matias and C. Calhaz-Jorge, *Endocrine*, 2018, **61**, 144–148.
- 10 Y. H. Quek, W. W. S. Tam, M. W. B. Zhang and R. C. M. Ho, *Obes. Rev.*, 2017, **18**, 742–754.
- 11 Y. J. Tak and S. Y. Lee, *Curr. Obes. Rep.*, 2021, **10**, 14–30.
- 12 A. M. Chao, T. A. Wadden, R. I. Berkowitz, K. Quigley and F. Silvestry, *Expert Opin. Drug Saf.*, 2020, **19**, 1095–1104.
- 13 R. Khera, A. Pandey, A. K. Chandar, M. H. Murad, L. J. Prokop, I. J. Neeland, J. D. Berry, M. Camilleri and S. Singh, *Gastroenterology*, 2018, **154**, 1309–1319.
- 14 M. Rodriguez-Guerra, M. Yadav, M. Bhandari, A. Sinha, J. N. Bella and E. Sklyar, *Case Rep. Cardiol.*, 2021, **2021**, 8896932.
- 15 K. A. Packard, R. L. Wurdeman and P. R. Antonio, *Ann. Pharmacother.*, 2002, **36**, 1168–1170.
- 16 M. H. Amy, A. C. Karim, R. M. Jennifer, E. C. Suzanne and A. Y. Jack, *Ann. Pharmacother.*, 2002, **36**, 1003–1005.
- 17 A. M. Chao, T. A. Wadden and R. I. Berkowitz, *Expert Opin. Drug Saf.*, 2018, **17**, 379–385.
- 18 A. J. Krentz, K. Fujioka and M. Hompesch, *Diabetes, Obes. Metab.*, 2016, **18**, 558–570.
- 19 P. Lauren and A. S. Mike, *Neurology*, 2013, **80**, 773–774.
- 20 R. A. João and M. Fátima, *Curr. Neuropharmacol.*, 2012, **10**, 49–52.
- 21 H. H. Hansen, J. Perens, U. Roostalu, J. L. Skytte, C. G. Salinas, P. Barkholt, D. D. Thorbek, K. T. G. Rigbolt, N. Vrang, J. Jelsing and J. Hecksher-Sorensen, *Mol. Metab.*, 2021, **47**, 101171.
- 22 C. Q. Moreira, M. J. S. S. Faria, J. E. Baroneza, R. J. Oliveira and E. G. Moreira, *Hum. Exp. Toxicol.*, 2005, **24**, 397–402.
- 23 R. L. Cunha, W. A. Lopes and P. A. P. Pereira, *Microchem. J.*, 2016, **125**, 230–235.
- 24 M. Sarikaya, H. I. Ulusoy, U. Morgul, S. Ulusoy, A. Tartaglia, E. Yilmaz, M. Soylak, M. Locatelli and A. Kabir, *J. Chromatogr. A*, 2021, **1648**, 462215.
- 25 C. Viana, G. M. Zemolin, L. S. Muller, T. R. Dal Molin, H. Seiffert and L. M. de Carvalho, *Food Addit. Contam., Part A: Chem., Anal., Control, Exposure Risk Assess.*, 2016, **33**, 1–9.
- 26 J. Yun, K. J. Shin, J. Choi and C. H. Jo, *Forensic Sci. Int.*, 2018, **286**, 199–207.
- 27 T. L. Pedersen, I. J. Gray and J. W. Newman, *Anal. Chim. Acta*, 2021, **1143**, 189–200.
- 28 Z. Qian, J. Le, X. Chen, S. Li, H. Song and Z. Hong, *J. Sep. Sci.*, 2018, **41**, 618–629.
- 29 L. M. Tazi and S. Jayawickreme, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1011**, 89–93.
- 30 B. F. Da Silva, A. Ahmadireskety, J. J. Aristizabal-Henao and J. A. Bowden, *MethodsX*, 2020, **7**, 101111.
- 31 T. Margaryan, M. Sargsyan, A. Gevorgyan, H. Zakaryan, A. Aleksanyan, A. Harutyunyan, Y. Armoudjian and A. Mikayelyan, *Biomed. Chromatogr.*, 2020, **34**, e4844.
- 32 J. M. M. Kahl, K. F. da Cunha, L. C. Rodrigues, K. O. Chinaglia, K. D. Oliveira and J. L. Costa, *J. Pharm. Biomed. Anal.*, 2021, **196**, 113928.
- 33 M. Kertys, M. Krivosova, I. Ondrejka, I. Hrtanek, I. Tonhajzerova and J. Mokry, *J. Pharm. Biomed. Anal.*, 2020, **181**, 113098.
- 34 Y. Li, R. Cleary, M. Kellogg, J. S. Soul, G. T. Berry and F. E. Jensen, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2011, **879**, 998–1002.
- 35 J. W. Bae, C. I. Choi, C. G. Jang and S. Y. Lee, *Biomed. Chromatogr.*, 2011, **25**, 1181–1188.
- 36 A. M. Teitelbaum, A. M. Flaker and E. D. Kharasch, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1017–1018**, 101–113.
- 37 L. Wagmann, S. Hemmer, A. T. Caspar and M. R. Meyer, *Clin. Chem. Lab. Med.*, 2020, **58**, 664–672.
- 38 C. Mariotti Kde, R. S. Schuh, P. Ferranti, R. S. Ortiz, D. Z. Souza, F. Pechansky, P. E. Froehlich and R. P. Limberger, *J. Anal. Toxicol.*, 2014, **38**, 432–437.

